Peripheral Blood Plasma DNA Sequencing for MDS Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing myelodysplastic syndromes (MDS) are challenging, especially at early stages, due to subjective morphologic evaluations and the invasive nature of bone marrow biopsies, which are painful and not always reliable, particularly for patients with normal karyotypes and low blast counts.
Innovation Solution
A method utilizing next-generation sequencing (NGS) on cell-free DNA from peripheral blood plasma or serum to identify mutations in MDS-associated genes without the need for bone marrow samples, combining NGS with PCR and hybrid capture for enhanced sensitivity and accuracy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bone marrow biopsy is used for MDS diagnosis, then diagnostic reliability is improved, but patient suffering and procedural complexity increase
Solution Approach 1:
The invention extracts the diagnostic function from the invasive bone marrow biopsy procedure and relocates it to a non-invasive peripheral blood test. By analyzing cell-free DNA and mutant clones in peripheral blood, the method achieves reliable MDS diagnosis without requiring bone marrow extraction, thus eliminating patient suffering while maintaining diagnostic accuracy.
Solution Approach 2:
The invention introduces cell-free DNA from peripheral blood as an intermediary medium for diagnosis. Instead of directly examining bone marrow tissue, the method uses circulating DNA fragments as a surrogate that carries genetic information about the bone marrow condition, enabling indirect but reliable assessment of MDS without invasive procedures.
2Ease of operation
If subjective morphologic evaluation is used for MDS diagnosis, then diagnostic simplicity is improved, but measurement precision deteriorates
Solution Approach 1:
The invention replaces the mechanical/visual assessment system (microscopic examination of bone marrow morphology) with a molecular analysis system. By using next-generation sequencing to detect mutant clones and genetic abnormalities in cell-free DNA, the method substitutes subjective visual judgment with objective, quantifiable molecular data, thereby improving measurement precision while maintaining diagnostic accessibility.
3Ease of operation
If peripheral blood cell DNA is used for molecular analysis, then sample accessibility is improved, but detection sensitivity deteriorates
Solution Approach 1:
The invention extracts cell-free DNA from peripheral blood plasma, separating it from cellular components. This extracted cell-free DNA serves as a more sensitive marker for mutant clones compared to DNA from intact peripheral blood cells, because it directly reflects the genetic abnormalities present in the bone marrow environment without being diluted by normal cellular DNA.
4Measurement precision
If next-generation sequencing is applied to cell-free DNA, then detection sensitivity is improved, but device complexity and cost increase
Solution Approach 1:
The invention uses cell-free DNA as an intermediary that concentrates mutant clone signals, making them more detectable by sequencing technologies. This intermediary approach amplifies the target signal before analysis, thereby reducing the relative complexity and cost burden of the sequencing system itself, as the preliminary enrichment of mutant DNA fragments occurs naturally in the cell-free fraction.
Data Source
Figure 1
Figure 2
AI summary
Methods are provided for treating, managing, diagnosing and monitoring myelodysplastic syndrome and other hematologic malignancies. These methods comprise the next generation sequencing analysis conducted on cell-free DNA from peripheral blood plasma or serum.